Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics, based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials
Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival (PFS), which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
Health technology and clinical wearables are hot topics in the healthcare and pharmaceutical industries. They are creating waves of excitement and talking points for debate, while also topping many of the healthcare trends of this year.
The AMA and Google are joining forces on an mHealth challenge designed to improve care coordination for people with chronic conditions through mobile health platforms linking the patient with the doctor.
AI technology is already in use in certain aspects of healthcare, such as diagnostic imaging, but it’s being underutilized in several others.
Ddu, the leading global pharmaceutical & medical device B2B online platform, is currently attending global exhibitions, leaving its footprints at multiple word-class medical trade shows in South Korea, India, Chongqing (China), Turkey and the United States.
Novo Nordisk has moved into sickle cell disease through a licensing deal (PDF) with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
In June, 2017, the Drug Regulatory Authority of Pakistan (DRAP) issued Statutory Notifications (S.R.O) 470 (I)/2017, a new regulation stating that imported and exported drugs should realize serialization and meet the barcode label requirements for the product track and trace system in six months.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.